Table 1 Demographics and baseline characteristics of the study population
Demographics and Clinical Characteristics | |||
|---|---|---|---|
Reporting ≥ 1 postdromal symptoms | |||
Yes n = 511 | No n = 120 | Overall n = 631 | |
Gender, n (%) | |||
Female | 464 (90.8%) | 98 (81.7%) | 562 (89.1%) |
Male | 47 (9.2%) | 22 (18.3%) | 69 (10.9%) |
Age, mean (SD) | 44.9 (11.8) | 43.4 (12.9) | 44.6 (12.0) |
BMI, mean (SD) | 25.0 (4.9) | 25.0 (5.2) | 25.0 (5.0) |
Race, n (%) | |||
White | 469 (91.8%) | 115 (95.8%) | 584 (92.6%) |
Middle Eastern or North African | 31 (6.1%) | 5 (4.2%) | 36 (5.7%) |
Black | 6 (1.2%) | 0 (0%) | 6 (1.0%) |
Asian or Pacific Islander | 4 (0.8%) | 0 (0%) | 4 (0.6%) |
Hispanic or Latin American | 1 (0.2%) | 0 (0%) | 1 (0.2%) |
Native American | 0 (0%) | 0 (0%) | 0 (0%) |
Headache Diagnoses, n (%)a | |||
Migraine without Aura | 502 (98.2%) | 118 (98.3%) | 620 (98.3%) |
Migraine with Aura | 166 (32.5%) | 32 (26.7) | 198 (31.4%) |
Chronic Migraine | 300 (58.7%) | 80 (66.7%) | 380 (60.2%) |
Medication Overuse Headache | 179 (35.0%) | 43 (35.8%) | 222 (35.2%) |
Headache Frequency, mean (SD) | |||
Monthly Migraine Days | 13.7 (6.1) | 18.6 (9.4) | 14.6 (7.1) |
Total Headache Days Per Month | 17.2 (6.5) | 20.8 (8.4) | 17.9 (7.1) |
Migraine Intensity, n (%) | |||
Mild | 1 (0.2%) | 2 (1.7%) | 3 (0.5%) |
Moderate | 148 (29.0%) | 37 (30.8%) | 185 (29.3%) |
Severe | 362 (70.8%) | 81 (67.5%) | 443 (70.2%) |
Clinical Features, n (%) | |||
Pulsating | 392 (76.7%) | 87 (72.5%) | 479 (75.9%) |
Pressing | 226 (44.2%) | 65 (54.2%) | 291 (46.1%) |
Aggravated by physical activity | 465 (91.0%) | 106 (88.3%) | 571 (90.5%) |
Presence of Nausea | 481 (94.1%) | 107 (89.2%) | 588 (93.2%) |
Presence of Photophobia | 492 (96.3%) | 112 (93.3%) | 604 (95.7%) |
Presence of Phonophobia | 481 (94.1%) | 105 (87.5%) | 586 (92.9%) |
Presence of Autonomic Symptoms | 291 (56.9%) | 51 (42.5%) | 342 (54.2%) |
Current Use of Treatment, n (%) | |||
Current Use of Acute Medication | 501 (98.0%) | 115 (95.8%) | 616 (97.6%) |
Current Use of Triptans | 469 (91.8%) | 101 (84.2%) | 570 (90.3%) |
Current Use of Preventive Medication | 291 (56.9%) | 59 (49.2%) | 350 (55.5%) |
Reports Premonitory Symptoms, n (%) | 413 (80.8%) | 34 (28.3%) | 447 (70.8%) |
Reports Trigger Factors, n (%) | 493 (96.5%) | 113 (94.2%) | 606 (96.0%) |